|
ACTN1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.445900E-04 |
| Normal-vs-Stage3 |
7.4031003549635E-11 |
| Normal-vs-Stage4 |
3.2588998166716E-10 |
| Stage1-vs-Stage2 |
5.735400E-03 |
| Stage1-vs-Stage3 |
3.898200E-01 |
| Stage1-vs-Stage4 |
6.673600E-01 |
| Stage2-vs-Stage3 |
5.521200E-03 |
| Stage2-vs-Stage4 |
1.136280E-02 |
| Stage3-vs-Stage4 |
7.077600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
1.385620E-04 |
| Normal-vs-Asian |
1.85950144171443E-11 |
| Caucasian-vs-AfricanAmerican |
8.399600E-01 |
| Caucasian-vs-Asian |
4.242400E-01 |
| AfricanAmerican-vs-Asian |
4.526600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.66522351463527E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
5.754200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.53240000022592E-07 |
| Normal-vs-Age(81-100Yrs) |
1.500490E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.239630E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.138000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.456400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.032800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.025000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.765600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.667240E-01 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
2.936000E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
1.387570E-04 |
| Tall-VS-Other |
6.899800E-02 |
| Tall-VS-Normal |
2.32449999999496E-05 |
| Follicular-VS-Other |
2.223900E-02 |
| Follicular-VS-Normal |
6.984500E-02 |
| Other-VS-Normal |
2.873500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.87072579649339E-12 |
| Normal-vs-N1 |
9.83435555212964E-12 |
| N0-vs-N1 |
4.217200E-03 |
|
|
